SEC Comment Letter for Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425) (MIRM) — Jun 3, 2022
Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)
Date: June 3, 2022 · CIK: 0001759425 · Accession: 0000000000-22-006071
AI Filing Summary & Sentiment
File numbers found in text: 333-265210
Letter
United States securities and exchange commission logo June 3, 2022 Christopher Peetz President and Chief Executive Officer Mirum Pharmaceuticals, Inc. 950 Tower Lane, Suite 1050 Foster City, California 94404 Re:Mirum Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 25, 2022 File No. 333-265210 Dear Mr. Peetz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Alexa Ekman, Esq.
Show Raw Text
United States securities and exchange commission logo
June 3, 2022
Christopher Peetz
President and Chief Executive Officer
Mirum Pharmaceuticals, Inc.
950 Tower Lane, Suite 1050
Foster City, California 94404
Re:Mirum Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed May 25, 2022
File No. 333-265210
Dear Mr. Peetz:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Alexa Ekman, Esq.